Literature DB >> 19861681

Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.

Connie Duckers1, Paolo Simioni, Luca Spiezia, Claudia Radu, Paolo Dabrilli, Sabrina Gavasso, Jan Rosing, Elisabetta Castoldi.   

Abstract

Coagulation factor V (FV), present in plasma and platelets, is indispensable to thrombin formation, yet patients with undetectable plasma FV seldom experience major bleeding. We used thrombin generation assays to explore the role of platelet FV in 4 patients with severe congenital FV deficiency (3 with plasma FV clotting activity [FV:C] < 1%). When triggered with tissue factor (TF) concentrations up to 50pM, platelet-poor plasma (PPP) from the patients with undetectable plasma FV showed no thrombin generation, whereas platelet-rich plasma (PRP) formed thrombin already at 1 to 5pM of TF. Thrombin generation in PRP from the FV-deficient patients was enhanced to near-normal levels by platelet activators (collagen or Ca(2+)-ionophore) and could be completely suppressed by specific FV inhibitors, suggesting FV dependence. Accordingly, platelet FV antigen and activity were measurable in all FV-deficient patients and platelet FVa could be visualized by Western blotting. Normalization of the tissue factor pathway inhibitor (TFPI) level, which is physiologically low in FV-deficient plasma, almost completely abolished thrombin generation in PRP from the FV-deficient patients. In conclusion, patients with undetectable plasma FV may contain functional FV in their platelets. In combination with low TFPI level, residual platelet FV allows sufficient thrombin generation to rescue these patients from fatal bleeding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861681     DOI: 10.1182/blood-2009-08-237719

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides.

Authors:  Matthew W Bunce; Mettine H A Bos; Sriram Krishnaswamy; Rodney M Camire
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

2.  Isolated factor V deficiency in a patient with elevated PT and aPTT during routine pre-operative laboratory screening.

Authors:  Keyur Thakar; Kaushal Parikh; Yamei Chen; Delong Liu
Journal:  Stem Cell Investig       Date:  2014-02-08

Review 3.  The intersection of protein disulfide isomerase and cancer associated thrombosis.

Authors:  Jack D Stopa; Jeffrey I Zwicker
Journal:  Thromb Res       Date:  2018-04       Impact factor: 3.944

4.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

5.  Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency.

Authors:  Beth A Bouchard; John Chapin; Kathleen E Brummel-Ziedins; Peter Durda; Nigel S Key; Paula B Tracy
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

6.  Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes.

Authors:  Claudia Zappelli; Carmen van der Zwaan; Daphne C Thijssen-Timmer; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

7.  Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study.

Authors:  Joline L Saes; Marieke J A Verhagen; Karina Meijer; Marjon H Cnossen; Roger E G Schutgens; Marjolein Peters; Laurens Nieuwenhuizen; Felix J M van der Meer; Ilmar C Kruis; Waander L van Heerde; Saskia E M Schols
Journal:  Blood Adv       Date:  2020-10-27

8.  Acquired factor V deficiency in a patient without evidence of a classical inhibitor.

Authors:  I R Sosa; P Ellery; A Mast; A T Neff; D Gailani
Journal:  Haemophilia       Date:  2013-10-14       Impact factor: 4.287

9.  Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.

Authors:  Jack D Stopa; Donna Neuberg; Maneka Puligandla; Bruce Furie; Robert Flaumenhaft; Jeffrey I Zwicker
Journal:  JCI Insight       Date:  2017-01-12

10.  Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.

Authors:  F Ayombil; S Abdalla; P B Tracy; B A Bouchard
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.